|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Arch Pathol Lab Med 138:241-256, 2014) in addition to serving as surrogate markers for molecular alterations in neoplasms, including IDH1 and ATRX mutations in brain tumors (Appin CL, Brat DJ.Mol Aspects Med.45:87-96, 2015).
|
30539453 |
2019 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias.
|
22343896 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our findings indicate that CDKN2A/B risk genotypes are associated with primary glioblastoma without IDH mutation, and that there is an inverse association between RTEL1 risk genotypes and 1p/19q codeletion, suggesting that these genetic variants have a molecular impact on the genesis of high graded brain tumors.
|
26839018 |
2016 |
|
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Patients with wild-type IDH1 brain tumors and high podoplanin expression had a significantly increased VTE risk compared with those with mutant IDH1 tumors and no podoplanin expression (6-month risk 18.2% vs. 0%).
|
29676036 |
2018 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
|
19903171 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors.
|
22015945 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
|
23111198 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss.
|
28640702 |
2017 |
|
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used human glioma tissues and derived brain tumor stem cells (BTSCs) to study the expression of HIF1α target genes in IDH mutant ((mt)) and IDH wild-type ((wt)) tumors.
|
24366912 |
2014 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
20160062 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here, we describe the isolation of a glioma brain tumor stem cell line (BT142) with an endogenous R132H mutation in IDH1, aggressive tumor-initiating capacity, and 2-HG production.
|
22166263 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
|
22427879 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To address this, we analyzed IDH1(R132) and IDH2(R172) mutation status 53 metastatic brain tumors, including nine melanoma metastases.
|
20603105 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This study demonstrates the feasibility, specificity, and selectivity of using MR detection and quantification of 2HG for the diagnosis and classification of IDH1/2 mutation-positive brain tumors.
|
22426639 |
2012 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal lobe.
|
25225364 |
2014 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Exon 4 of IDH1 and IDH2 was analyzed in a series of brain tumors classified according to current WHO criteria.
|
29535392 |
2018 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
|
18985363 |
2008 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Another mitochondrial and TCA cycle-related protein, isocitrate dehydrogenase 2 is, together with IDH1, frequently mutated in the brain tumour glioblastoma.
|
20304625 |
2010 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
|
23558169 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Brain Neoplasms
|
0.500 |
CausalMutation
|
group |
CGI |
|
|
|